Free Trial

XBiotech, AstraZeneca rise; Churchill Downs, Gilead fall

NEW YORK (AP) — Stocks that moved heavily or traded substantially Monday:

XBiotech, Inc., up $1.21 to $19.57.

The biotechnology company's antibody screening technology will benefit from the FDA's emergency authorization of plasma for COVID-19 patients.

Catalent Inc., up $1.97 to $88.46.

The maker of drug delivery systems expanded its manufacturing support deal with AstraZeneca for a potential COVID-19 vaccine.

Churchill Downs Inc., down $1.69 to $172.54.

The racetrack operator and gambling company will run the 146th Kentucky Derby without fans in attendance.

AstraZeneca Plc., up $1.05 to $56.76.

The U.S. is considering fast-tracking the drug developer's potential COVID-19 vaccine, according to media reports.

JPMorgan Chase & Co., up $2.74 to $100.06.

Banks made broad gains as global markets rallied around hopes for a coronavirus vaccine and continued economic recovery.

American Airlines Group Inc., up $1.28 to $13.44.

Airlines made gains as hopes for a COVID-19 vaccine raised the possibility that demand for travel will recover.

Gilead Sciences Inc., down 42 cents to $66.08.

The biotechnology company's drug remdesivir showed disappointing results as a COVID-19 treatment in a published study.

Barrick Gold Corp., down 34 cents to $28.97.

The price of gold slipped as investors turned away from safe-play holdings.

Should You Invest $1,000 in Barrick Gold Right Now?

Before you consider Barrick Gold, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Barrick Gold wasn't on the list.

While Barrick Gold currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Gilead Sciences (GILD)
4.9586 of 5 stars
$112.49-1.4%2.81%22.41Moderate Buy$117.17
JPMorgan Chase & Co. (JPM)
4.5983 of 5 stars
$312.55-0.7%1.79%16.04Moderate Buy$292.78
Churchill Downs (CHDN)
4.9675 of 5 stars
$95.830.6%0.43%16.47Buy$136.50
Catalent (CTLT)
0.9714 of 5 stars
$63.48flatN/A-28.09Hold$63.50
American Airlines Group (AAL)
4.0507 of 5 stars
$12.33-1.0%N/A15.41Moderate Buy$16.59
Barrick Gold (ABX)
1.6906 of 5 stars
C$48.947.4%0.82%30.78BuyC$37.33
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Related Videos

Top Trades: Massive Gains and Costly Mistakes to Avoid

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines